Compare ORIO & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORIO | ITRM |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Canada | Ireland |
| Employees | 188 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0M | 24.3M |
| IPO Year | N/A | 2018 |
| Metric | ORIO | ITRM |
|---|---|---|
| Price | $0.90 | $0.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 46.7K | ★ 30.9M |
| Earning Date | 03-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $74.52 | N/A |
| Revenue Next Year | $5.07 | $947.65 |
| P/E Ratio | $4.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $0.03 |
| 52 Week High | $1.40 | $1.16 |
| Indicator | ORIO | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 26.10 |
| Support Level | N/A | N/A |
| Resistance Level | $0.98 | $0.39 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 18.86 | 3.34 |
Orion Digital Corp is a financial technology company operating digital platforms across wealth and payments, supported by a consumer lending business in Canada. The Company's Wealth platform, Intelligent Investing, provides long-term investment solutions to the Canadian market. It also operates a consumer lending business in Canada. Its Payments business is conducted through its wholly owned subsidiary, which provides issuer processing, program management, and regulated payment orchestration services across Europe. The Company operates in Canada and Europe, with Canada generating the majority of its revenue.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.